Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study

MLA

Miguel J. Gil-Gil, et al. “Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study.” Frontiers in Oncology, vol. 11, July 2021. EBSCOhost, https://doi.org/10.3389/fonc.2021.645026.

APA

Miguel J. Gil-Gil, Meritxell Bellet, Milana Bergamino, Serafín Morales, Agustí Barnadas, Luís Manso, Cristina Saura, Adela Fernández-Ortega, Elena Garcia-Martinez, Noelia Martinez-Jañez, Mireia Melé, Patricia Villagrasa, Pamela Celiz, X. Perez Martin, Eva Ciruelos, & Sonia Pernas. (2021). Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study. Frontiers in Oncology, 11. https://doi.org/10.3389/fonc.2021.645026

Chicago

Miguel J. Gil-Gil, Meritxell Bellet, Milana Bergamino, Serafín Morales, Agustí Barnadas, Luís Manso, Cristina Saura, et al. 2021. “Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study.” Frontiers in Oncology 11 (July). doi:10.3389/fonc.2021.645026.